Ian C Brett
Affiliation: State University of New York
- Variation in the divalent cation requirements of influenza a virus N2 neuraminidasesBert E Johansson
Department of Pediatrics, Division of Critical Care Medicine, Weill Medical College of Cornell University, 525 East 68th St, Box 437, New York, NY 10021, USA
J Biochem 134:345-52. 2003....
- Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model systemIan C Brett
Department of Pediatrics, Division of Pediatric Critical Care Medicine, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
Virology 339:273-80. 2005..These studies suggest that vaccines immunogenic for both HA and NA offer an increased level of protection from influenza...
- Variation in the divalent cation requirements of influenza A virus N1 neuraminidasesIan C Brett
Department of Pediatrics, Division of Critical Care Medicine, Weill Medical College of Cornell University, 525 East 68th St, New York, NY 10021, USA
J Biochem 139:439-47. 2006..Selection of vaccine strains must include analysis of antigenic changes, but also enzymatic studies and determination of the requirement of divalent cations to maintain immunogenicity and activity during production...
- An inactivated subvirion influenza A (H5N1) vaccineBert E Johansson
N Engl J Med 354:2724-5; author reply 2724-5. 2006
- Changing perspective on immunization against influenzaBert E Johansson
Innovation Sciences, Armonk, NY 10504, USA
Vaccine 25:3062-5. 2007..Alternative production technologies such as recombinant baculovirus and yeast should be explored to decrease vaccine production times...
- Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccinesBert E Johansson
Innovation Sciences, Armonk, New York 10504, USA
Hum Vaccin 4:420-4. 2008..This report demonstrates with influenza B virus, in a side-by-side comparison with CIV and LAIV in a murine model system the superiority of vaccines containing immunogenic NA over currently approved CIV and LAIV vaccines...